Cargando…
Immune checkpoint blockade can synergize with radiation therapy, even in tumors resistant to checkpoint monotherapy
Immunotherapy has evolved as a new pillar of cancer treatment during the last decade. The main breakthrough was the development of immune checkpoint blocking (ICB) antibodies, which antagonize inhibitory receptors on T cells and their ligands and thus unleash the cellular immune system against the t...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286364/ https://www.ncbi.nlm.nih.gov/pubmed/27965270 http://dx.doi.org/10.15252/emmm.201607219 |